Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial

Table 4 Summary of concomitant medication usage

Period of concomitant medication use relative to lasmiditan administration	Concomitant medication type	Number of times concomitantly administered n (%)^a
From 24 h to immediately prior to lasmiditan administration	Ergot alkaloids	1 (0.0)
	NSAIDs	251 (2.9)
	Triptans	112 (1.3)
From 0 to < 2 h after lasmiditan administration	Ergot alkaloids	0
	NSAIDs	96 (1.1)
	Triptans	64 (0.7)
From 2 to < 24 h after lasmiditan administration	Ergot alkaloids	12 (0.1)
	NSAIDs	471 (5.4)
	Triptans	365 (4.2)

N number of migraine attacks treated with lasmiditan, n number of migraine attacks treated with lasmiditan in combination with other acute treatment, NSAIDs nonsteroidal anti-inflammatory drugs
^aPercentages were calculated based on the number of times the concomitant medication was administered divided by the total number of times lasmiditan was administered (N = 8654)

ISSN: 1129-2377